- Open
- 6.60
- High
- 6.70
- Low
- 6.35
- Close
- 6.63
- Change
- -0.30 (-4.48%)
- Volume
- 1,485,408
| 23 Jul 2026 | 07:00:04 | H1 2026 Trading Update |
| 13 Jul 2026 | 07:00:10 | Change of Auditor |
| 9 Jun 2026 | 07:00:03 | Holding(s) in Company |
| 1 Jun 2026 | 12:00:00 | Consultancy contract with Decoy Therapeutics |
| 29 May 2026 | 07:00:04 | Grant of awards under Long Term Incentive Plan |
| 9 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Oct 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Oct 2024 | Annual Report and Accounts (to 2023-12-31) |
Hvivo plc acts as a holding company with investments in its wholly owned subsidiaries, hVIVO Services Limited and hVIVO Inc. The primary business activity of hVIVO Services Limited involves conducting human challenge studies and providing laboratory services for clinical trials on behalf of commercial clients. The company serves the biopharmaceutical sector, focusing on accelerating the development of new therapies. It operates primarily in the United Kingdom and has minority investments in associates, including Prep Biopharm Limited and Imutex Limited.
| 23 Jul 2026 | 07:00:04 | H1 2026 Trading Update |
| 13 Jul 2026 | 07:00:10 | Change of Auditor |
| 9 Jun 2026 | 07:00:03 | Holding(s) in Company |
| 1 Jun 2026 | 12:00:00 | Consultancy contract with Decoy Therapeutics |
| 29 May 2026 | 07:00:04 | Grant of awards under Long Term Incentive Plan |
| 9 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Oct 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 8 Oct 2024 | Annual Report and Accounts (to 2023-12-31) |
Hvivo plc acts as a holding company with investments in its wholly owned subsidiaries, hVIVO Services Limited and hVIVO Inc. The primary business activity of hVIVO Services Limited involves conducting human challenge studies and providing laboratory services for clinical trials on behalf of commercial clients. The company serves the biopharmaceutical sector, focusing on accelerating the development of new therapies. It operates primarily in the United Kingdom and has minority investments in associates, including Prep Biopharm Limited and Imutex Limited.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £12m | +0.6% | |
| £12m | +0.4% | |
| £11m | -0.6% | |
| £7m | -0.4% | |
HVOHvivo PLC | £6m | -0.4% |
| £2m | -1.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £12m | +0.6% | |
| £12m | +0.4% | |
| £11m | -0.6% | |
| £7m | -0.4% | |
HVOHvivo PLC | £6m | -0.4% |
| £2m | -1.0% |
